The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study
Open accessAbstract
BACKGROUND: Barrett’s oesophagus, columnar metaplasia of the epithelium, is a premalignant condition with a 50–100-fold increased risk of cancer. The condition is caused by chronic gastro-oesophageal reflux. Regression of metaplasia may decrease the cancer risk. AIMS: To determine whether elimination of acid gastro-oesophageal reflux induces a regression of metaplastic epithelium. METHODS: Sixty eight patients with acid reflux and proven Barrett’s oesophagus were included in a prospective, randomised, double blind study with parallel groups, and were treated with profound acid secretion suppression with omeprazole 40 mg twice daily, or with mild acid secretion suppression with ranitidine 150 mg twice daily, for 24 months. Endoscopy was performed at 0, 3, 9, 15, and 24 months with measurement of length and surface area of Barrett’s oesophagus; pH-metry was performed at 0 and 3 months. Per protocol analysis was performed on 26 patients treated with omeprazole, and 27 patients treated with ranitidine. RESULTS: Omeprazole reduced reflux to 0.1%, ranitidine to 9.4% per 24 hours. Symptoms were ameliorated in both groups. There was a small, but statistically significant regression of Barrett’s oesophagus in the omeprazole group, both in length and in area. No change was observed in the ranitidine group. The difference between the regression in the omeprazole and ranitidine group was statistically significant for the area of Barrett’s oesophagus (p=0.02), and showed a trend in the same direction for the length of Barrett’s oesophagus (p=0.06). CONCLUSIONS: Profound suppression of acid secretion, leading to elimination of acid reflux, induces partial regression of Barrett’s oesophagus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Histologic Spectrum of Barrett's Esophagus
Paull, A., Trier, J. S., Dalton, M. D., Camp, R. C., Loeb, P., & Goyal, R. K. (1976) · New England Journal of Medicine · doi:10.1056/nejm197608262950904 · Cited by 755
Adenocarcinoma and Barrett's esophagus. An overrated risk?
Spechler, S. J., Robbins, A. H., Rubins, H. B., et al. (1984) · PubMed · Cited by 437
Chow, W.-H. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530060048032 · Cited by 365
Barr, H., Shepherd, N., Dix, A., Roberts, D., Tan, W., & Krasner, N. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03054-1 · Cited by 303
Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium
Berenson, M. M., Johnson, T. D., Markowitz, N. R., Buchi, K. N., & Samowitz, W. S. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90646-t · Cited by 242
Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus
Menke-Pluymers, M. B. E., Hop, W. C. J., Dees, J., van Blankenstein, M., & Tilanus, H. W. (1993) · Cancer · doi:10.1002/1097-0142(19930815)72:4<1155::aid-cncr2820720404>3.0.co;2-c · Cited by 224
Katzka, D. A., & Do, C. (1994) · PubMed · Cited by 221
Esophageal Acid Sensitivity in Barrettʼs Esophagus
Johnson, D. A., Winters, C., Spurling, T. J., Chobanian, S. J., & Cattau, E. L. (1987) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-198702000-00006 · Cited by 199
Sharma, P., Sampliner, R. E., & Camargo, E. (1997) · PubMed · Cited by 193
Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy
GORE, S., HEALEY, C. J., SUTTON, R., EYRE‐BROOK, I. A., GEAR, M. W. L., SHEPHERD, N. A., & WILKINSON, S. P. (1993) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1993.tb00143.x · Cited by 180
Cited by
Sharma, P., Dent, J., Armstrong, D., Bergman, J. J. G. H. M., Gossner, L., Hoshihara, Y., Jankowski, J. A., Junghard, O., Lundell, L., Tytgat, G. N. J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.032 · Cited by 1,049
Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus
El-Serag, H. B., Aguirre, T. V., Davis, S., Kuebeler, M., Bhattacharyya, A., & Sampliner, R. E. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30228.x · Cited by 331
Epidemiology of upper gastrointestinal malignancies
CREW, K. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.04.021 · Cited by 323
Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions
Song, H., Zhu, J., & Lu, D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010623.pub2 · Cited by 132
The potential role for photodynamic therapy in the management of upper gastrointestinal disease
Barr, H., Dix, A. J., Kendall, C., & Stone, N. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.00936.x · Cited by 40
Metadata
- Authors
- Peters, F. T. M., Ganesh, S., Kuipers, E. J., Sluiter, W. J., Klinkenberg-Knol, E. C., Lamers, C. B. H. W., & Kleibeuker, J. H.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 1999-10-01
- Volume
- 45
- Issue
- 4
- Pages
- 489-494
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2125451295
- Cited by
- 264
- References
- 17
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. https://app.cochat.ai/papers/10.1136/gut.45.4.489
- The paper
- Peters, F. T. M., Ganesh, S., Kuipers, E. J., Sluiter, W. J., Klinkenberg-Knol, E. C., Lamers, C. B. H. W., & Kleibeuker, J. H. (1999). Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. Gut. https://doi.org/10.1136/gut.45.4.489
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.